2cureX (2CUREX) H2 2024 earnings summary

Executive summary

• 2024 marked a major transformation, with a failed distributor-led strategy prompting leadership changes and a split into 2cureX AB (public) and 2cureX A/S (private).

• 2cureX AB will focus on direct-to-patient commercialization and acquisitions; 2cureX A/S will drive product development and regulatory expansion.

• Daniel Honeywell was appointed CEO in December 2024 to lead growth and innovation.

• IndiTreatⓇ remains central, with a new strategy to accelerate global commercialization and patient access.

• The company is committed to delivering value for patients and investors amid ongoing transformation.

Financial highlights

• No net sales or operating income reported for H2 or full year 2024.

• Net loss for H2 2024 was -3,249 KSEK (vs. -1,246 KSEK H2 2023); full year net loss was -4,128 KSEK (vs. -2,471 KSEK 2023).

• Cash and cash equivalents at year-end 2024 were 5,140 KSEK (vs. 1,459 KSEK at end 2023).

• Cash flow for 2024 was 3,681 KSEK (vs. -37,856 KSEK in 2023), mainly due to investment inflows and financing.

• Equity ratio declined to 66% at year-end 2024 (from 93% at end 2023).

Outlook and guidance

• Additional investment expected in 2025 to fund the new strategy.

• 2cureX AB will pursue direct-to-patient sales and acquisitions; 2cureX A/S will focus on product development and regulatory milestones.

• IndiTreatⓇ positioned for global expansion and leadership in precision oncology.

• Upcoming financial reports scheduled for April and August 2025.